Stocks and Investing
Stocks and Investing
Fri, March 15, 2013
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:00 AM ] - United States, Market Wire
[ 06:00 AM ] - United States, Market Wire
[ 05:30 AM ] - United States, Market Wire
[ 04:30 AM ] - United States, Market Wire
[ 04:00 AM ] - United States, Market Wire
[ 03:48 AM ] - United States, WOPRAI
[ 03:47 AM ] - United States, WOPRAI
[ 03:47 AM ] - United States, WOPRAI
[ 03:47 AM ] - United States, WOPRAI
[ 03:46 AM ] - United States, WOPRAI
[ 03:46 AM ] - United States, WOPRAI
[ 03:45 AM ] - United States, WOPRAI
[ 03:45 AM ] - United States, WOPRAI
[ 02:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Amsellem Maintained (SUPN) at Buy with Decreased Target to $14 on, Mar 15th, 2013
David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Decreased Target from $15 to $14 on, Mar 15th, 2013.
David has made no other calls on SUPN in the last 4 months.
There is 1 other peer that has a rating on SUPN. Out of the 1 peers that are also analyzing SUPN, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- David Steinberg of "Jefferies" Initiated at Strong Buy and Held Target at $13 on, Tuesday, March 5th, 2013
Contributing Sources